SG Americas Securities LLC Makes New $92,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

SG Americas Securities LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMAGet Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 46,423 shares of the biotechnology company’s stock, valued at approximately $92,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. CTC Capital Management LLC purchased a new position in ADMA Biologics during the 1st quarter worth approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ADMA Biologics during the 1st quarter worth approximately $40,000. Eagle Asset Management Inc. grew its position in ADMA Biologics by 55.4% during the 1st quarter. Eagle Asset Management Inc. now owns 28,833 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 10,281 shares in the last quarter. Stratos Wealth Partners LTD. purchased a new position in ADMA Biologics during the 1st quarter worth approximately $73,000. Finally, Lazard Asset Management LLC grew its position in ADMA Biologics by 18.5% during the 1st quarter. Lazard Asset Management LLC now owns 46,876 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 7,309 shares in the last quarter. 60.77% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 2.5 %

ADMA stock opened at $3.16 on Thursday. The company has a current ratio of 5.04, a quick ratio of 1.38 and a debt-to-equity ratio of 1.51. ADMA Biologics, Inc. has a 1 year low of $1.17 and a 1 year high of $3.47. The company has a fifty day simple moving average of $2.68 and a 200 day simple moving average of $2.34. The firm has a market cap of $620.49 million, a PE ratio of -8.54 and a beta of 1.00.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of research reports. HC Wainwright decreased their target price on shares of ADMA Biologics from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, July 25th. Mizuho lifted their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, November 10th. Finally, StockNews.com initiated coverage on shares of ADMA Biologics in a research note on Wednesday, October 12th. They set a “sell” rating for the company.

ADMA Biologics Company Profile

(Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Recommended Stories

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMAGet Rating).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.